BIO vs SNDX · rev $651.0M vs rev $137.7M
BIO (BIO) versus Syndax Pharmaceuticals Inc (SNDX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Syndax Pharmaceuticals Inc (SNDX) is a biotechnology company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported SNDX revenue for 2026-06-30 was $137.7M. Net income was -$92.0M. SNDX currently screens at market cap $774.4M.
BIO currently screens at market cap $0. SNDX currently screens at market cap $774.4M.
Not investment advice. Open the BIO and SNDX stock pages for the full models.
Not investment advice.